Complex pathways to ceftolozane-tazobactam resistance in clinical *Pseudomonas*

***aeruginosa* isolates: a genomic epidemiology study**

Hoai-An Nguyen[1], Anton Y. Peleg[1,2,3], Jiangning Song[3,4], Jessica A. Wisniewski[1†], Luke V.

Blakeway[1†], Gnei Z. Badoordeen[1†], Ravali Theegala[1†], Nhu Quynh Doan[1], Matthew H. Parker[1],

David L. Dowe[5] and Nenad Macesic*[1,3]

[1]Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine,

Monash University, Melbourne, Australia.

[2]Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University,

Melbourne, Australia.

[3]Centre to Impact AMR, Monash University, Melbourne, Australia

[4]Monash Biomedicine Discovery Institute, Department of Biochemistry & Molecular Biology,

Monash University, Melbourne, Australia

[5]Department of Data Science & AI, Monash University, Melbourne, Australia.

* Corresponding Author

Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of

Translational Medicine, Monash University, Level 1, The Alfred Lane House, 11 Alfred Ln,

Melbourne, VIC 3004, Australia.

nenad.macesic1@monash.edu

†No longer at the institution where the work was performed.

Keywords:

Ceftolozane/tazobactam, antimicrobial resistance, *Pseudomonas aeruginosa*, genome-wide

association studies, machine learning.

Abstract

Objectives

We aimed to conduct a comprehensive genomic analysis of ceftolozane/tazobactam (C/T)

resistance mechanisms in *Pseudomonas aeruginosa* by combining novel institutional data

with publicly available sequencing data.

Methods

We analysed 1,682 *P. aeruginosa* isolates, comprising 339 isolates from Alfred Hospital

(Melbourne, Australia) and 1,343 isolates from six public datasets. All isolates underwent

whole-genome sequencing and C/T broth microdilution (BMD) susceptibility testing. We

assessed previously reported intrinsic and acquired resistance mechanisms. We then

conducted a genome-wide association study (GWAS) and machine learning analysis to

identify novel genes associated with resistance. We then evaluated the impact of mutations in

these genes on MIC values and ceftolozane binding affinity.

Results

Among 1,682 *P. aeruginosa* isolates representing 527 distinct sequence types, 343/1,682

(20.4%) were C/T-resistant. Carbapenemase genes were detected in 206/1,682 (12.2%)

isolates. Mutations in previously reported resistance-associated genes (*ftsI, mpl, ampD,*

ampC, ampR, oprD) were more frequent in resistant isolates but were also found in almost all

susceptible isolates. Successive mutations conferred additive increases in MIC. Combined GWAS and machine learning analyses *a priori* identified five key genes significantly associated with resistance: *ftsI*, *ampR*, *ampC*, PA3329, and PA4311. Molecular docking simulation revealed that the R504C mutation in penicillin-binding protein 3 (PBP3), which is encoded by *ftsI*, reduced binding contacts and hydrogen bonds with ceftolozane, significantly decreasing binding affinity (P=0.016).

Conclusions

Our analysis of 1,682 *P. aeruginosa* genomes demonstrated complex pathways to C/T resistance and showed that *ftsI* may play an underappreciated role. We discovered two previously unidentified genes associated with C/T resistance, whose function remains to be determined.

Introduction

Pseudomonas aeruginosa is a key Gram-negative pathogen, accounting for 9.4% of global antimicrobial resistance (AMR)-attributable deaths in 2021[1]. Multidrug-resistant (MDR) *P. aeruginosa* forms 15-30% of total *P. aeruginosa* infections[2], severely limiting available treatment options. Consequently, ceftolozane-tazobactam (C/T) has emerged as a first-line treatment for MDR *P. aeruginosa* infections[3]. However, rates of C/T resistance in MDR *P. aeruginosa* can be as high as 18.4%[4]. This highlights the urgent need to understand C/T resistance mechanisms, in order to rapidly identify resistant isolates and better control their spread.

There are multiple pathways contributing to C/T resistance[5]. Of these, structural alterations in AmpC β-lactamase represent most common mechanism[6-8]. AmpC hyperproduction, resulting from mutations in regulatory genes (*ampD*, *ampR*, *dacB,* and *mpl*), also confers resistance[6,7]. Acquired AMR genes such as carbapenemases or extended-spectrum β-lactamases represent another major mechanism due to their ability to hydrolyse ceftolozane[8,9].

Previous studies on C/T resistance have largely focused on case series and well-described mechanisms[7,8,10]. However, the complex interplay between different resistance mechanisms remains poorly understood, and the identification of novel resistance determinants has been limited. To address these gaps, we aimed to comprehensively determine C/T resistance mechanisms using novel data from our institution combined with all publicly-available *P. aeruginosa* genomes with matched C/T susceptibility phenotypes. Specifically, we aimed to assess prevalence of known resistance mechanisms, then identify novel mechanisms through a genome-wide association study (GWAS) and machine learning (ML) approaches (**Figure 1**).

Materials and methods

Bacterial isolate collection

The study was reviewed and approved by the Alfred Hospital Ethics Committee (Project No.

185/21). We analysed 339 *P. aeruginosa* isolates collected between 2004-2021 at the Alfred

Hospital (Melbourne, Australia), a 638-bed quaternary hospital with a cystic fibrosis and lung

transplant state referral service. Consecutive *P. aeruginosa* isolates were recovered from

clinical specimens. The isolates consisted of both matt and mucoid morphotypes and were

stored in glycerol broth at –80°C. Repeat isolates from the same patient were included if they

had a different morphotype and/or susceptibility profile (as determined by Vitek 2; BioMérieux,

France) and were collected more than a week apart. All isolates underwent short-read

sequencing (Illumina) (see **Supplementary Methods**).

We identified six public datasets containing both whole-genome sequencing (WGS) data and

antimicrobial susceptibility testing (AST) results[5,11-15]. To ensure standardised resistance

determination, we included only datasets where minimum inhibitory concentrations (MIC) were

determined using broth microdilution (BMD), the reference method. The in-house sequence

files have been deposited in NCBI project ID PRJNA1220180.

Antimicrobial susceptibility testing

For our in-house isolates, we conducted BMD using the ThermoFisher Sensititre plate (code:

DKMGN) to determine C/T MIC values. We used the European Committee on Antimicrobial

Susceptibility Testing (EUCAST) v15.0 breakpoints (MIC $\leq$ 4mg/L) to classify isolates as

'susceptible' or 'resistant'[16].

WGS data processing

De novo short-read assembly was generated using Unicycler v0.5.0[17]. Species confirmation and multi-locus sequence typing (MLST) were conducted via Pathogenwatch (https://pathogen.watch). Acquired AMR genes were detected using AMRFinderPlus v3.11.18[18]. For chromosomal mutations analysis, we assessed mutations in ten genes previously linked to C/T resistance, as described by Cortes-Lara et al.[5]. Additionally, we included *oprD* due to its involvement in resistance following C/T exposure (see Supplementary Methods)[7].

Identifying variants associated with C/T resistance

We conducted GWAS on susceptible/resistant phenotypes using a mixed-effects model implemented in pyseer v1.3.10[19]. Unitigs were used as testing variants, with a phylogeny-based pairwise distance matrix incorporated to control for population structure (see Supplementary Methods). Association mapping was performed using the annotated PAO1 reference genome (Genbank: GCA_000006765.1). To reduce false positives and computational load, we applied a two-step filtering strategy: first identifying GWAS-significant variants, then retaining only those that also contributed to ML-based C/T resistance prediction (see Supplementary Methods).

Binding affinity analysis

We assessed the binding affinity between ceftolozane and proteins encoded by GWAS-significant genes, comparing both wild-type and mutant variants. 3D structures of proteins

132 were predicted using ColabFold, an AlphaFold-based tool[20]. Molecular docking simulations

133 were performed using AutoDock Vina v1.2.5[21], and results were visualised using PyMOL[22].

Results

Data characteristics

We analysed 1,682 *P. aeruginosa* genomes from four continents (Asia, Europe, North

America, Oceania) (**Supplementary File 1**), including Alfred Hospital isolates (339/1,682,

20.2%) and six public datasets (1,343/1,682, 79.8%)[5,11-15]. C/T resistance was noted in

343/1,682 (20.4%) isolates. We detected 527 sequence types (STs) (**Supplementary Figure**

1). *P. aeruginosa* ST235, a well-recognised global MDR lineage was most frequent

(163/1,682, 9.7%) and accounted for 78/343 (22.7%) of C/T resistant isolates. Resistance

rates in common ST groups can be found in **Supplementary Table 1**.

Prevalence of acquired AMR genes

We first analysed acquired C/T resistance determinants. Carbapenemase genes were noted

in 206/1,682 (12.2%) isolates (**Supplementary Table 2**), including serine carbapenemase

(*bla*$_{GES}$, *bla*$_{KPC}$) and metallo-*β*-lactamase genes (*bla*$_{IMP}$, *bla*$_{VIM}$, *bla*$_{NDM}$). Carbapenemase

acquisition strongly predicted C/T resistance, with 202/206 (98.1%) carbapenemase-positive

isolates being C/T resistant. Only *bla*$_{GES-5}$ was found in C/T-susceptible isolates (4/206, 1.9%).

The most common carbapenemase was *bla*$_{NDM-1}$ (37/206, 18.0%), followed by *bla*$_{IMP-4}$

(31/206, 15.0%), *bla*$_{IMP-1}$ (29/206, 14.1%), *bla*$_{VIM-2}$ (25/206, 12.1%) and *bla*$_{GES-5}$ (22/206,

10.7%). Dual carbapenemases were identified in six isolates. The *bla*$_{OXA-50}$ family was

excluded from analysis as these enzymes are intrinsic to *P. aeruginosa*[23]. Among acquired

bla$_{OXA}$ genes, *bla*$_{OXA-10}$, *bla*$_{OXA-14}$, *bla*$_{OXA-141}$, *bla*$_{OXA-210}$, and *bla*$_{OXA-796}$ were significantly more

prevalent in C/T-resistant isolates (**Supplementary Figure 2**). VEB-type β-lactamases were detected only in C/T-resistant isolates (8/343, 2.0%), with 4/8 co-harboring additional carbapenemases: two with bla_{KPC-2}, one with bla_{VIM-5}, and one with bla_{NDM-1}.

Analyses of known chromosomal C/T resistance mechanisms

We then assessed prevalence of mutations in a curated list of eleven intrinsic genes associated with C/T resistance (*ampC* and its regulators, mexAB-oprM overexpression pathway, *ftsI, galU* and *oprD*, **Figure 2A-C, Supplementary Table 3**)[5]. We specifically excluded isolates with acquired resistance determinants that likely conferred C/T resistance alone (carbapenemase genes, VEB β-lactamases, acquired OXA β-lactamases with significantly higher prevalence in resistant isolates), as the impact of additional mutations would be unclear. This resulted in a subset of 1,447 isolates (including 115 resistant isolates), which we will refer to as the 'intrinsic resistance' dataset. Mutations in genes associated with resistance were noted in all resistant isolates but also in 1,323/1,332 (99.3%) susceptible isolates, however the majority of these have previously been described as natural polymorphisms (**Supplementary Table 3**)[5].

We therefore focused on mutations with a previously reported high impact on C/T susceptibility. These were significantly more frequent in resistant than susceptible isolates (in order of significance): *ftsI* (24/115 resistant vs. 22/1,332 susceptible isolates, $P=4.11\times10^{-28}$), *ampC* (19/115 vs 55/1,332, $P=2.58\times10^{-8}$), *mpl* (12/115 vs. 44/1,332, $P=3.82\times10^{-4}$), *ampD* (9/115 vs 37/1,332, $P=0.007$), and *ampR* (13/115 vs 73/1,332, $P=0.02$). In terms of specific mutations, for *ftsI* the R504C mutation was most prevalent (21/115 [18.3%] resistant vs 17/1332 [1.3%] susceptible isolates). Notably, it was distributed across 18 unique STs in the

resistant group. The previously reported F533L and E466K mutations were not found in C/T-

resistant isolates[24,25]. For known *ampC* mutations[26], E247G was detected in one resistant and

one susceptible isolate. Deletions in the G229-E247 region (△G at L237, △P241-A246, and

△R238-L244) were found in four resistant isolates and no susceptible isolates.

Inactivated *oprD* was also more frequent in resistant isolates (77/115 [66.9%] vs 626/1,332

[47,0%], *P*=6.03×10^{-5}). Frameshift due to indels was the most common mutation in both

resistant (26/115, 22.6%) and susceptible (249/1,332, 18.7%) isolates. For other canonical

C/T resistance genes, mutations in the *mexAB-oprM* efflux pump regulators (*nalC*, *nalD*, and

mexR) were very frequent in the resistant group, occurring in 111/115 (96.5%). Mutations in

galU and *dacB* were noted in 3/115 (2.6%) and 39/115 (33.9%) resistant isolates, respectively.

Analysis of combinations of mutations in C/T resistance-associated genes revealed 67 distinct

mutational pathways in resistant isolates (**Figure 2B**). Multiple mutations were common, with

only 1/67 (1.5%) pathways involving a single mutation. Notably, all resistant isolates

harboured at least one mutation in either *ampC* or its overexpression regulators (*ampR*,

ampD, *mpl, dacB*). At the AMR mechanism level, collapsing *ampC*-related genes and *mexAB-*

oprM-related genes into functional groups revealed seven distinct resistance pathways (Figure

2C). Among these, only modifications in AmpC and its regulatory genes emerged as a

standalone pathway capable of conferring C/T resistance. While AmpC overexpression

represents the main mechanism of resistance to C/T, additional mechanisms are often

required to reach high-level resistance, highlighting the complexity of the mutational resistome

in *P. aeruginosa*.

We next investigated the impact of multiple mutations on MIC, firstly by including both low-

and high-impact mutations (**Figure 2D**, **Supplementary Figure 3A**), then high-impact

mutations only (**Figure 2E**, **Supplementary Figure 3B**). In both analyses, we observed an

increasing trend in MIC with a higher number of mutations. High-impact mutations were

associated with higher MIC increases, with a single mutation able to achieve resistant MICs

(mean: 4.73 mg/L, SD: 11.64, **Figure 2E**) per EUCAST breakpoints (4 mg/L). When

considering both low- and high-impact mutations, six or more mutations were required to

achieve the same effect (**Figure 2D)**.

Identifying novel C/T resistance mechanisms through GWAS and ML analysis

Using the 'intrinsic resistance' dataset (n=1,447), we conducted GWAS and identified 311

significant variants out of 2,698,635 tested unitigs (**Supplementary Figure 4**). Mapping to the

PAO1 reference genome annotated 280 unitigs corresponding to 73 genes (**Supplementary**

Table 4). Top associated genes included *ftsI* (P=5.05×10^{-23}), *hsbR* (P=5.85×10^{-20}), *ampR*

(P=3.52×10^{-18}), *ampC* (P=6.50×10^{-15}), and several hypothetical proteins, including PA3329

(P=1.47×10^{-15}), PA4311 (P=6.86×10^{-15}), and PA2418 (P=1.58×10^{-13}) (**Figure 3A**).

We then developed ML models to predict binary C/T resistance using the same dataset,

achieving an average area under receiver operator curve (AUROC) of 0.65, and log-loss of

0.26 (**Supplementary Figure 5**). Across all model iterations, 386 unitigs were selected. To

refine the list of candidates, we intersected GWAS-significant unitigs with those selected by

the models, applying thresholds of a minimum allele frequency above 0.1 and presence in

more than 5 model iterations (**Figure 3B**, **Supplementary Table 4**). This filtering yielded five

key genes: *ftsI* and *ampR* were selected in all models, while PA3329, PA4311, and *ampC*

appeared in 9/10, 7/10, and 6/10 models, respectively.

Binding affinity assessment for significant variants

ftsI emerged as a key determinant of C/T resistance in analysis of known resistance

mechanisms, as well as GWAS/ML analysis. These findings and the fact that PBP3 is a target

of ceftolozane prompted investigation of mutation impacts on *in silico* binding affinity[27]. We

identified four non-synonymous mutations in GWAS-significant unitigs mapped to *ftsI*: R504C

(n=38), F507I (n=1), T514A (n=1), and R504H (n=1). Among these, only R504C was

significantly associated with resistant isolates (21/115 [18.3%], $P=2.30\times10^{-26}$) while the others

were exclusively found in susceptible isolates. Molecular docking analysis revealed

significantly higher binding affinity between ceftolozane and wild type PBP3 compared to

mutant PBP3 (R504C) (-3.520 vs -2.814 kcal/mol, *P*=0.016) (**Supplementary Figure 6**), with

loss of contact at A244 and single hydrogen bonds at Q265 and T267 (cf. double bonds in wild

type PBP3) (**Figure 4**). These changes potentially explain reduced drug binding and

consequent resistance.

We extended our docking analysis to the novel proteins encoded by PA3329 and PA4311. The

PA3329-encoded protein showed no meaningful binding affinity to ceftolozane (mean: 924.393

kcal/mol, SD: 288.148). The PA4311-encoded protein demonstrated binding affinity (-1.493

kcal/mol, 1.459) with potential binding sites at D116, Q271, R292 and G294 (**Supplementary**

Figure 7).

Putative functions of novel C/T resistance determinants

To understand putative functions of PA3329 and P4311, we examined their genomic

neighbourhood, predicted Gene Ontology functions[28] and conducted a database and literature

search (see **Supplementary Methods** and **Supplementary Table 5)**. PA3329 is located in an

eight-gene operon (PA3327-PA3334) that includes *fabH2* (beta-keto-acyl-ACP synthase) and

acp3 (acyl carrier protein), suggestive of lipid/lipopolysaccharide synthesis[29,30]

(**Supplementary Figure 8)**. The predicted Gene Ontology terms for PA3329 indicate a role in

cellular anatomical structure **(Supplementary Table 5)**. PA3329 has also been implicated in

the CreBC two-component system which is involved in β-lactam stress response[31]. PA4311 is

annotated as a glycosyltransferase[32]

(https://www.pseudomonas.com/feature/show?id=111460). The predicted Gene Ontology

terms also indicate glycosyltransferase activity and a role in cellular anatomical structure

(**Supplementary Table 5**). In *P. aeruginosa*, glycosyltransferase reactions are essential for

lipopolysaccharide synthesis, which is located in the outer leaflet of the outer membrane[33].

Based on this evidence, we hypothesise that both PA3329 and PA4311 are involved in outer

membrane remodelling that affects ceftolozane influx.

Discussion

This comprehensive genomic analysis of 1,682 *P. aeruginosa* isolates has revealed multiple

mechanisms contributing to C/T resistance, including previously known resistance

determinants (*ftsI*, *ampC*, and *ampR*) and novel candidates (PA3329 and PA4311). *ftsI*

emerged as a key contributor to C/T resistance across multiple analyses. These findings were

underscored by several methodological strengths. Our study leveraged a large, geographically

diverse dataset incorporating both novel and public genome sequences to provide robust

statistical power and broad representativeness. Additionally, our multi-modal approach, which

combines GWAS, ML, and molecular docking, enabled cross-validation of findings through complementary methodologies.

Ceftolozane is a potent inhibitor of PBP3 encoded by *ftsI*[27]. Our study noted that mutations in *ftsI* were highly associated with C/T resistance, being present in 24/115 resistant vs 22/1,332 susceptible isolates ($P=4.11\times10^{-28}$), specifically the R504C mutation. This was then further confirmed in our GWAS and ML analyses, which both identified *ftsI* as the top-ranking contributor to C/T resistance. Our docking analysis then demonstrated that mutant *ftsI* (R504C) significantly reduced ceftolozane binding affinity, providing a mechanistic explanation for resistance. The role of PBP3 in β-lactam resistance has been increasingly recognised, not only in *P. aeruginosa*[7], but also across various Enterobacterales[34,35]. Although the R504C mutation was previously documented to emerge following C/T exposure[10], its importance in C/T resistance has potentially been underappreciated, as research has primarily focused on β-lactamases[8,36]. Furthermore, its co-occurrence with other mutations may have obscured its individual contribution to resistance[7,8,10], highlighting the value of GWAS approach in identifying specific resistance determinants.

Our analysis of genes previously associated with C/T resistance[5] showed that they likely have differing contributions when studied in a diverse international dataset. We applied a multi-modal approach to assess the contribution of resistance genes by applying both a traditional genomic analysis looking at genes associated with C/T resistance in the literature, and GWAS and ML approaches to allow us to identify key resistance genes *a priori.* Mutations in *ampC* and its regulator genes were found in all resistant isolates. Amongst these some were confirmed to have strong contributory effects (e.g. *ampC* and *ampR*) but others contributed

less (e.g. GWAS suggested limited contributions from *ampD*). In some C/T resistance genes

we detected very few mutations (e.g., *galU* in 2.6% of resistant isolates). These findings

highlight the complex nature of C/T resistance mechanisms in *P. aeruginosa*. To try to account

for some of these interactions, we assessed the impact of multiple mutations and noted

stepwise increases in MIC with the number of mutations, both when considering all non-

synonymous mutations and when considering high-impact mutations alone.

The contribution of horizontally acquired β-lactamase genes to C/T resistance has been well

described[8,9], specifically key carbapenemases including bla_{VIM}, bla_{IMP}, bla_{NDM}, and bla_{KPC}.

While we noted these carbapenemases in 12.2% isolates in our study, we also showed that

specific bla_{OXA} and bla_{VEB} genes may play an important role. Four bla_{OXA} genes (bla_{OXA-14},

$bla_{OXA-141}$, $bla_{OXA-210}$, and $bla_{OXA-796}$) and all bla_{VEB} genes were found exclusively in resistant

isolates. These findings confirm prior studies that identified bla_{OXA} gene acquisition as a

common cause of C/T resistance (particularly bla_{OXA-14})[8], as well as noting an association

between bla_{VEB} gene acquisition and C/T resistance[37].

Our study had several limitations. Firstly, the retrospective nature of the analysis and potential

sampling bias in the dataset may affect generalisability. Secondly, while docking analysis

suggests reduced ceftolozane binding to mutant PBP3, in vitro studies are required to confirm

these findings. Lastly, we hypothesised that PA3329 and PA4311 are involved in outer

membrane remodelling however future functional validation is crucial to testing this hypothesis

and determining their role in resistance. However, the emergence of mutations and

interactions between multiple genes complicates the identification of key resistance drivers.

In conclusion, our study rigorously determined the genetic underpinnings of C/T resistance

and revealed complex pathways leading to C/T resistance. *ampC* and its regulators were

confirmed to play an important role but we demonstrated that *ftsI* may be a more significant

contributor than previously recognised. We also identified two novel determinants whose

functions remain to be determined. The hypotheses generated by our study present an

opportunity for validation through both computational and experimental approaches to

understand the functional mechanisms of these newly identified determinants.

Author contributions

HA.N, N.M. and A.Y.P. conceived the study. J.A.W. designed and supervised sampling and

collection of bacterial isolates. J.A.W., L.V.B., G.Z.B, R.T., N.Q.D., and M.H.P. collected the

bacterial isolates, performed bacterial characterization, conducted genome sequencing and

broth microdilution. HA.N. preprocessed WGS data. HA.N., J.S., D.L.D., and N.M.

conceptualised machine learning analyses. HA.N. conducted GWAS, developed machine

learning models. HA.N. and N.M. analysed all results. HA.N. and N.M. wrote the manuscript

with comments and feedback of all of the co-authors. All authors read and approved the

manuscript.

Funding

342 This work was supported by the National Health and Medical Research Council of Australia

343 (Emerging Leader 1 Fellowship APP1176324 to N.M. and Practitioner Fellowship

344 APP1117940 to A.Y.P) and the Australian Medical Research Future Fund (FSPGN000048).

345 The funders had no role in study design, data collection and interpretation, or the decision to

346 submit the work for publication.

Competing interests

N.M. has received research support from GlaxoSmithKline, unrelated to the current study. A.Y.P. has received research funding from MSD through an investigator-initiated research project. All other authors declare no conflict of interest.

Acknowledgement

This work was supported by Monash eResearch Centre, including the M3 service. This work was also supported by use of the Nectar Research Cloud, a collaborative Australian research platform supported by the NCRIS-funded Australian Research Data Commons (ARDC).

References

1.   Naghavi M, Vollset SE, Ikuta KS, et al. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. *The Lancet*. 2024;404(10459):1199-1226. doi:10.1016/S0140-6736(24)01867-1

2.   Horcajada JP, Montero M, Oliver A, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clinical Microbiology Reviews*. 2019;32(4):10.1128/cmr.00031-19. doi:doi:10.1128/cmr.00031-19

3.   Macesic N, Uhlemann A-C, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. *The Lancet*. 2025;405(10474):257-272. doi:10.1016/s0140-6736(24)02081-6

4.   Kostoulias X, Chang CC, Wisniewski J, et al. Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant *Pseudomonas aeruginosa* isolates from Melbourne, Australia. *Pathology*. 2023;55(5):663-668. doi:10.1016/j.pathol.2023.03.009

5.   Cortes-Lara S, Barrio-Tofiño Ed, López-Causapé C, et al. Predicting *Pseudomonas aeruginosa* susceptibility phenotypes from whole genome sequence resistome analysis. *Clinical Microbiology and Infection*. 2021;27(11):1631-1637. doi:10.1016/j.cmi.2021.05.011

6.   Cabot G, Bruchmann S, Mulet X, et al. *Pseudomonas aeruginosa* Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. *Antimicrobial Agents and Chemotherapy*. 2014;58(6):3091-3099. doi:doi:10.1128/aac.02462-13

7.   Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. *Clinical Infectious Diseases*. 2020;73(11):e4599-e4606. doi:10.1093/cid/ciaa1306

8. Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam
resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*.
Journal of Antimicrobial Chemotherapy. 2017;73(3):658-663. doi:10.1093/jac/dkx424

9. Karlowsky JA, Lob SH, Estabrook MA, et al. Susceptibility profile and β-lactamase content of
global *Pseudomonas aeruginosa* isolates resistant to ceftolozane/tazobactam and/or
imipenem/relebactam—SMART 2016–21. *JAC-Antimicrobial Resistance*.
2023;5(3)doi:10.1093/jacamr/dlad080

10. Rubio AM, Kline EG, Jones CE, et al. *In Vitro* Susceptibility of Multidrug-Resistant *Pseudomonas*
aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. *Antimicrobial*
Agents and Chemotherapy. 2021;65(6):10.1128/aac.00084-21. doi:doi:10.1128/aac.00084-21

11. Barrio-Tofiño Ed, López-Causapé C, Cabot G, et al. Genomics and Susceptibility Profiles of
Extensively Drug-Resistant *Pseudomonas aeruginosa* Isolates from Spain. *Antimicrobial Agents and*
Chemotherapy. 2017;61(11):10.1128/aac.01589-17. doi:doi:10.1128/aac.01589-17

12. del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, et al. Spanish nationwide survey on
Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. *Journal of*
Antimicrobial Chemotherapy. 2019;74(7):1825-1835. doi:10.1093/jac/dkz147

13. Teo Jocelyn Q-M, Lim Jie C, Tang Cheng Y, et al. Ceftolozane/Tazobactam Resistance and
Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. *mSphere*.
2021;6(1):10.1128/msphere.01026-20. doi:10.1128/msphere.01026-20

14. Stanton RA, Campbell D, McAllister GA, et al. Whole-Genome Sequencing Reveals Diversity of
Carbapenem-Resistant *Pseudomonas aeruginosa* Collected through CDC's Emerging Infections
Program, United States, 2016-2018. *Antimicrobial Agents and Chemotherapy*. 2022;66(9):e00496-22.
doi:doi:10.1128/aac.00496-22

15. Sastre-Femenia MÀ, Fernández-Muñoz A, Gomis-Font MA, et al. *Pseudomonas aeruginosa*
antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-
year time lapse analysis. *The Lancet Regional Health – Europe*.
2023;34doi:10.1016/j.lanepe.2023.100736

16. European Committee on Antimicrobial Susceptibility Testing (EUCAST). *Breakpoint tables for*
interpretation of MICs and zone diameters. Version 15.0, valid from 2025-01-01. 2023.

17. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from
short and long sequencing reads. *PLOS Computational Biology*. 2017;13(6):e1005595.
doi:10.1371/journal.pcbi.1005595

18. Feldgarden M, Brover V, Gonzalez-Escalona N, et al. AMRFinderPlus and the Reference Gene
Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response,
and virulence. *Scientific Reports*. 2021/06/16 2021;11(1):12728. doi:10.1038/s41598-021-91456-0

19. Lees JA, Galardini M, Bentley SD, Weiser JN, Corander J. pyseer: a comprehensive tool for
microbial pangenome-wide association studies. *Bioinformatics*. 2018;34(24):4310-4312.
doi:10.1093/bioinformatics/bty539

20. Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making
protein folding accessible to all. *Nature Methods*. 2022/06/01 2022;19(6):679-682.
doi:10.1038/s41592-022-01488-1

21. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods,
Expanded Force Field, and Python Bindings. *Journal of Chemical Information and Modeling*.
2021/08/23 2021;61(8):3891-3898. doi:10.1021/acs.jcim.1c00203

22. Schrödinger LLC. The PyMOL Molecular Graphics System, Version 1.8. 2015.

23.   Mack Andrew R, Hujer Andrea M, Mojica Maria F, et al. β-Lactamase diversity in Pseudomonas
aeruginosa. *Antimicrobial Agents and Chemotherapy*. 2025;69(3):e00785-24. doi:10.1128/aac.00785-
24

24.   Hernández-García M, García-Castillo M, García-Fernández S, et al. Distinct epidemiology and
resistance mechanisms affecting ceftolozane/tazobactam in *Pseudomonas aeruginosa* isolates
recovered from ICU patients in Spain and Portugal depicted by WGS. *Journal of Antimicrobial*
Chemotherapy. 2020;76(2):370-379. doi:10.1093/jac/dkaa430

25.   Simner PJ, Beisken S, Bergman Y, Posch AE, Cosgrove SE, Tamma PD. Cefiderocol Activity Against
Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance. *Open Forum*
Infectious Diseases. 2021;8(7):ofab311. doi:10.1093/ofid/ofab311

26.   Díaz-Cañestro M, Periañez L, Mulet X, et al. Ceftolozane/tazobactam for the treatment of
multidrug resistant *Pseudomonas aeruginosa*: experience from the Balearic Islands. *European Journal*
of Clinical Microbiology & Infectious Diseases. 2018/11/01 2018;37(11):2191-2200.
doi:10.1007/s10096-018-3361-0

27.   Moyá B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the New Cephalosporin CXA-101 to
Penicillin-Binding Proteins of *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*.
2010;54(9):3933-3937. doi:doi:10.1128/aac.00296-10

28.   Kulmanov M, Guzmán-Vega FJ, Duek Roggli P, Lane L, Arold ST, Hoehndorf R. Protein function
prediction as approximate semantic entailment. *Nature Machine Intelligence*. 2024/02/01
2024;6(2):220-228. doi:10.1038/s42256-024-00795-w

29.   Therisod H, Weissborn AC, Kennedy EP. An essential function for acyl carrier protein in the
biosynthesis of membrane-derived oligosaccharides of Escherichia coli. *Proceedings of the National*
Academy of Sciences. 1986/10/01 1986;83(19):7236-7240. doi:10.1073/pnas.83.19.7236

30.   Chen W, Wang B, Gruber JD, Zhang Y-M, Davies C. Acyl Carrier Protein 3 Is Involved in Oxidative
Stress Response in Pseudomonas aeruginosa. Original Research. *Frontiers in Microbiology*. 2018-
September-20 2018;Volume 9 - 2018doi:10.3389/fmicb.2018.02244

31.   Zamorano L, Moyà B, Juan C, Mulet X, Blázquez J, Oliver A. The Pseudomonas aeruginosa CreBC
Two-Component System Plays a Major Role in the Response to β-Lactams, Fitness, Biofilm Growth, and
Global Regulation. *Antimicrobial Agents and Chemotherapy*. 2014;58(9):5084-5095.
doi:10.1128/aac.02556-14

32.   Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, Brinkman Fiona SL. Enhanced annotations and
features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database.
Nucleic Acids Research. 2016;44(D1):D646-D653. doi:10.1093/nar/gkv1227

33.   Maldonado RF, Sá-Correia I, Valvano MA. Lipopolysaccharide modification in Gram-negative
bacteria during chronic infection. *FEMS Microbiology Reviews*. 2016;40(4):480-493.
doi:10.1093/femsre/fuw007

34.   Le Terrier C, Nordmann P, Buchs C, Poirel L. Effect of modification of penicillin-binding protein 3
on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam,
aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing
broad-spectrum β-lactamases. *Antimicrobial Agents and Chemotherapy*. 2024;68(4):e01548-23.
doi:10.1128/aac.01548-23

35.   Mushtaq S, Vickers A, Woodford N, Livermore DM. Activity of aztreonam/avibactam and
ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem
resistance. *International Journal of Antimicrobial Agents*. 2024/03/01/ 2024;63(3):107081.
doi:https://doi.org/10.1016/j.ijantimicag.2023.107081

36.   Gomis-Font MA, Cabot G, López-Argüello S, et al. Comparative analysis of in vitro dynamics and
mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in
Pseudomonas aeruginosa XDR high-risk clones. *Journal of Antimicrobial Chemotherapy*.
2022;77(4):957-968. doi:10.1093/jac/dkab496
37.   Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205)
against *Pseudomonas aeruginosa* and *Burkholderia cepacia* group strains and isolates. *International*
Journal of Antimicrobial Agents. 2009/11/01/ 2009;34(5):402-406.
doi:https://doi.org/10.1016/j.ijantimicag.2009.03.021
478
479

481 **Figure 1. Overall workflow of the study.** This figure was created with BioRender.com.

Figure 2. (A) Impact of mutations in chromosomal genes known to affect C/T susceptibility. P-values were calculated using the Chi-square test. **(B) Pathways to C/T resistance at gene level.** Each unique combination of mutations in genes associated with C/T resistance is shown as a unique pathway. **(C) Distinct pathways to C/T resistance, collapsed to resistance mechanisms.** Here, the genes associated with C/T resistance are collapsed into mechanistic groupings. Each unique combination of mutations in mechanistic groupings is shown as a unique pathway. **(D, E) MIC values with respect to the cumulation of mutations (all non-synonymous mutations [D] vs high-impact mutations only [E]) in chromosomal genes known for C/T resistance.** Dots and vertical bars indicate mean and standard deviation (SD) of MIC values, respectively.

Figure 3. (A) Genes selected by GWAS study, with the maximum P-value (y-axis) and the average minimum allele frequency (MAF) (x-axis). (B) Genes (y-axis) selected by both GWAS and ML approach, and their occurrence in ML models (x-axis). Only genes with MAF > 0.1 are shown.

501 A.   B.

502 **Figure 4. 3D structure visualization of the interaction of ceftolozane (pink) to R504C**

503 **mutant PBP3 (Panel A) and wild type PBP3 (Panel B).** Dashed yellow lines indicate

504 hydrogen bonds. The R504C mutant (**Panel A**) shows loss of contact at A244 and single

505 hydrogen bonds at positions Q265 and T267 (cf. double bonds in wild type PBP3 – **Panel B**).